CCL3 promotes oxaliplatin resistance in gastric cancer via CCR5-mediated tumor cell survival and macrophage M2 polarization
{{output}}
Although oxaliplatin (Oxa)-based chemotherapy is a standard treatment for gastric cancer (GC), its clinical efficacy is frequently limited by the development of Oxa resistance. Chemokine CCL3 is linked to tumor growth, which can result in tumor-immune interact... ...
